Three-Million Women in the US Are Living With Breast Cancer
DUBLIN, Ireland - Overall approximately 3 million women in the US are living with breast cancer according to a report by Research and Markets entitled, “Breast Cancer Drug Pipeline Update 2007”. But, according to the report, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years.
The most dramatic decrease is seen in younger patients that are younger than 50 years. In the past decade the regulatory authorities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal antibody (Herceptin) as a treatment option for breast cancer. AstraZeneca reported increased sales of Arimidex during 2005 up 38% to $1.2 billion. Faslodex increased (+39%) to $140 million whereas Nolvadex decreased (-16%) to $114 million. Novartis reported that Femara increased it sell value by +30% to $326 million for the first 6 months in 2006. Net U.S. sales of Herceptin increased 56% to $747.2 million in 2005 and 18% to $479.0 million during 2004. According to UK estimates, the switching of 100,000 women from tamoxifen to Arimidex will cost nearly 100 million.
There are more than 170 companies active in the procecess of developing more than 250 candidates in the breast cancer pipeline, from preclincial to approved drugs. Targeted therapies are becoming increasingly important as a treatment strategy, especially in conjunction with cytotoxics.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.